Tag: distribution

MONTREAL, June 12, 2025 (GLOBE NEWSWIRE) -- Stingray (TSX: RAY. A; RAY.B), an industry leader in music and video content distribution, business services, and advertising solutions, proudly announces its contribution in the grand opening of BMO's new branch at CF Toronto Eaton Centre. This state-of-the-art, full-service branch features Stingray Business's cutting-edge digital signage solutions, highlighting the integration of advanced technology in customer experiences.

The BMO branch in the CF Toronto Eaton Centre is strategically located on the corner of Yonge and  Dundas near Sankofa Square, one of Toronto's busiest intersections and a vibrant hub of innovation and activity. Its two-story wraparound windows presented a unique opportunity to elevate BMO’s brand presence, showcase an innovative approach to marketing, while maintaining a welcoming and comfortable customer experience within the branch. To maximize this unique opportunity, BMO partnered with Stingray Business to implement an innovative digital signage solution.

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte^®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.

Driven by Stable Legacy Sales and Ongoing Cost Savings Initiatives

The global industrial robotics market is set to expand from USD 17.6 billion in 2025 to USD 39 billion by 2035, at a CAGR of 7.49%. Key segments include traditional and collaborative robots, with growth in payload and mobile robotics. Major players like ABB and FANUC lead in this evolving landscape.

Press release
Paris, 12 June 2025

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.